Introduction:
The DOAC score is a clinical prediction algorithm for estimating the risk of bleeding in patients with non-valvular Atrial Fibrillation [AF] on a Direct-Acting Oral Anticoagulant [DOAC].
The score was developed using data from RE-LY trail [Randomised Evaluation of Long-Term Anticoagulation Therapy], further developed using data in the GARFIELD-AF registry [Global Anticoagulant Registry in
the Field-Atrial Fibrillation] and then validated using the COMBINE-AF trials [A Collaboration Between Multiple Institutions to Better Investigate
Non-Vitamin K Antagonist
Oral Anticoagulant Use in Atrial
Fibrillation] and individuals
in the Quebec Régie de l’Assurance Maladie du
Québec and Med-Echo Administrative Databases
(RAMQ) administrative database.
The DOAC score was developed using data from the RE-LY study and in which patients received Dabigatran 150mg twice daily. The score was then refined using data from the GARFIELD-AF registry with patients on all DOACs - Apixaban, Edoxaban and Rivaroxaban.